Papapetropoulos Spyros has filed 5 insider transactions across 2 companies since June 2024.
Most recent transaction: a grant/award of 34559 shares of Neuphoria Therapeutics Inc. ($NEUP) on August 27, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 27, 2025 | Neuphoria Therapeutics Inc. | $NEUP | Papapetropoulos Spyros | President and CEO | A | Employee Stock Option (Right-to- Buy) | 34559 | $8.27 | 74,088.0000 | 0 | 87.43% | 0.00% |
| June 4, 2025 | Lipocine Inc. | $LPCN | Papapetropoulos Spyros | Director | A | Stock Option (Right to Buy) | 1764 | $3.20 | 7,174.0000 | 5,350,356 | 32.61% | 0.03% |
| April 16, 2025 | Neuphoria Therapeutics Inc. | $NEUP | Papapetropoulos Spyros | President and CEO | A | Employee Stock Option (Right-to-Buy) | 27000 | $5.16 | 39,529.0000 | 0 | 215.50% | 0.00% |
| April 16, 2025 | Neuphoria Therapeutics Inc. | $NEUP | Papapetropoulos Spyros | President and CEO | A | Employee Stock Option (Right-to-Buy) | 270000 | $5.16 | 282,529.0000 | 0 | 2155.00% | 0.00% |
| June 5, 2024 | Lipocine Inc. | $LPCN | Papapetropoulos Spyros | Director | A | Stock Option (Right to Buy) | 1764 | $7.05 | 5,410.0000 | 0 | 48.38% | 0.00% |